Domain Therapeutics
Edit

Domain Therapeutics

http://domaintherapeutics.com/
Last activity: 28.07.2023
Active
Categories: BioTechClinicDevelopmentDrugHealthTechITManufacturingMedtechResearch
[EN]

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors(GPCRs), one of the most important classes of drug targets. With teams at work in France and Canada, Domain operates multiple technologies aimed at validating targets and discovering first-in-class therapies (small molecules or antibodies). It creates a pipeline of high-value programs in immuno-oncology, neurology and rare diseases which are developed as proprietary programs up to early clinical phases or in collaboration with pharma partners.

[FR]

Domain Therapeutics est une société biopharmaceutique dédiée à la découverte et au développement de nouveaux candidats médicaments ciblant les récepteurs couplés aux protéines G (GPCR), l'une des classes de cibles médicamenteuses les plus importantes. Avec des équipes basées en France et au Canada, Domain exploite de multiples technologies visant à valider des cibles et à découvrir des thérapies de premier ordre (petites molécules ou anticorps), crée un pipeline de programmes de forte valeur ajoutée en immuno-oncologie, neurologie et maladies rares, développés seuls jusqu'aux premières phases cliniques ou en collaboration avec des partenaires pharmaceutiques.
Likes
53
Followers
360
Followers
5.06K
Mentions
11
Location: France, Grand Est, Illkirch-Graffenstaden
Employees: 51-200
Phone: +33 3 90 40 61 52
Total raised: $55.27M
Founded date: 2008

Investors 5

Funding Rounds 5

DateSeriesAmountInvestors
23.05.2022Series A$42MadMare Bio...
13.01.2020-$6.68M-
28.05.2019-$3.91M-
14.04.2014Grant$230K-
17.07.2012-$2.45M-

Mentions in press and media 11

DateTitleDescription
28.07.2023Latest Updates of 7 Viva's Portfolio CompaniesHONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies. It continuously breathes life into t...
27.07.2022Portfolio Highlights: Clinical and Financing Updates of AIxplorerBIO, Genhouse, VivaVision, Domain, Amberstone, Anji and QurAlisSHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, its p...
26.05.2022Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and ApeironSHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio...
10.05.2022adMare BioInnovations joins a $42m Series A financing in Domain TherapeuticsStrasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, annou...
10.05.2022Domain Therapeutics Raises $42M in Series A FinancingDomain Therapeutics, a Strasbourg, France- and Montreal, Canada-based biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, closed a US $...
08.06.2020Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in MontrealThe new company raises initial capital to develop transmembrane peptides against GPCRs to address high unmet needs. Montreal, Canada – June 8, 2020: CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and Pepti...
13.01.2020Domain Therapeutics Secures €6M in Debt FinancingDomain Therapeutics, a Strasbourg, France-based biopharmaceutical company, closed a €6m ($6.7M) debt financing. The French Public Investment Bank, Banque Populaire Alsace Lorraine Champagne, Credit Industriel et Commercial (CIC) and Caisse ...
28.05.2019Domain Therapeutics Raises €3.5M in FundingDomain Therapeutics, a Strasbourg, France-based biopharma company, secured €3.5M ($3.9M) in funding. Existing shareholder Seventure Partners made the investment. The company intends to use the funds to accelerate its next growth phase. Foun...
28.05.2019Term Sheet — Tuesday May 28A TALE OF MANY MANY MERGERS Hello again, Term Sheet readers! I hope y’all had a grill-filled Memorial Day. This is Lucinda, filling in for Polina who is on the West Coast until Friday. In the meantime, please send deals and thoughts to Luci...
14.04.2014Domain Therapeutics Receives $230K Second Grant from Michael J. Fox FoundationDomain Therapeutics, a Strasbourg, France- and Montreal, Canada-based biopharmaceutical company dedicated to altering course of Parkinson’s disease, received a second grant of $230k from The Michael J. Fox Foundation (MJFF). The grant will ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In